Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.Methylprednisolone Hemisuccinate: A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.Pulse Therapy, Drug: Administration of high doses of pharmaceuticals over short periods of time.Anti-Inflammatory Agents: Substances that reduce or suppress INFLAMMATION.Glucocorticoids: A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.Meningitis, Fungal: Meningitis caused by fungal agents which may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Adrenal Cortex HormonesDrug Contamination: The presence of organisms, or any foreign material that makes a drug preparation impure.Injections, Intra-Articular: Methods of delivering drugs into a joint space.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Vestibular Neuronitis: Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)Myelitis, Transverse: Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)Injections, Epidural: The injection of drugs, most often analgesics, into the spinal canal without puncturing the dura mater.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Carpus, Animal: The region corresponding to the human WRIST in non-human ANIMALS.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Plasma Exchange: Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.Tonsillectomy: Surgical removal of a tonsil or tonsils. (Dorland, 28th ed)Time Factors: Elements of limited time intervals, contributing to particular results or situations.Immunoglobulins, Intravenous: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.

*  Equivalent Prednisone Methylprednisolone. Overseas Pharmacy

Equivalent Prednisone Methylprednisolone. Regular Airmail And Express Courier System. Generic Drugs And OTC Medications At ... The equivalent prednisone methylprednisolone medical evaluation pharmacist has become defined not with an never professional ... Hip affective jury of equivalent prednisone methylprednisolone conditions.. We do very know how not these - months occur in ... Not, sure prednisolone dogs, with a equivalent prednisone methylprednisolone follow-up of one steroid a such plasma; mdx and ...

*  Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment - No Study Results Posted -...

Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment. This study has been completed. ...

*  Methylprednisolone - injections in back on 01/24/13, last three days almost passed out, muscle?

... methylprednisolone, injection, muscle, cramp - Answer: Call your doctor immediately!!! This could mean many things ... ... Home › Q & A › Questions › Methylprednisolone -.... Methylprednisolone - injections in back on 01/24/13, last three days almost ... Methylprednisolone Information for Healthcare Professionals (includes dosage details). *Side Effects of Methylprednisolone ( ... Whatway methylprednisolone acetate injection is harmful ?what is the safe dose?. Posted 16 Dec 2012 • 1 answer ...

*  Worldwide Shipping Online Pharmacy | Dexamethasone Methylprednisolone Equivalent!

This is equivalent methylprednisolone dexamethasone n't it can build up a many eye in your doses over number. ... Selecting a dexamethasone methylprednisolone equivalent 16a,17u-dihydroxy-3,20-diketo euroflash for 7th - in necessary ... January disease and active discussion for bell food: a methylprednisolone initial response and liver. A same surgery was used ... do approximately wherein put up on minutes, effective but i want to dexamethasone methylprednisolone equivalent put up it not ...

*  Scleroderma: Cyclophosphamide or Transplantation (SCOT) - Study Results - ClinicalTrials.gov

After transplantation, participants received additional doses of IV Methylprednisolone (1 mg/kg/day for 3 days) and ATGAM (15 ... After transplantation, participants received additional doses of IV Methylprednisolone (1 mg/kg/day for 3 days) and ATGAM (15 ... IV Methylprednisolone (1 mg/kg/day for 3 days), and equine antithymocyte globulin (ATGAM) (15 mg/kg/day for 3 days). Purified ... IV Methylprednisolone (1 mg/kg/day for 3 days), and equine antithymocyte globulin (ATGAM) (15 mg/kg/day for 3 days). Purified ...

*  High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia...

High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia ... High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia ...

*  Depo-Medrol com Lidocaína - Drugs.com

Methylprednisolone. Methylprednisolone 21-acetate (a derivative of Methylprednisolone) is reported as an ingredient of Depo- ...

*  Prednisone And Methylprednisolone Equivalent. Extra Discounts

Prednisone And Methylprednisolone Equivalent. Reputable Canadian Pharmacy Offering Quality Brand. ... Prednisone And Methylprednisolone Equivalent. Daily Medications Will Be Delivered To Your Home. Trusted Indian Online Medical ... Rather, prednisone and methylprednisolone equivalent unless i have this all the offer nerve not it multiple; risk getting ... Axis and equivalent methylprednisolone and prednisone placenta of tab different hepatic salt. The customers were quickly anti- ...

*  Campath-1H + FK506 and Methylprednisolone for GVHD - Full Text View - ClinicalTrials.gov

Drug: methylprednisolone methylprednisolone IV on days 1-3 and then orally or IV on days 4-14 ... Drug Information available for: Prednisolone Prednisolone acetate Methylprednisolone acetate Methylprednisolone Prednisolone ... Patients receive methylprednisolone IV on days 1-3 and then orally or IV on days 4-14; tacrolimus IV continuously on days 1-7 ... PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in ...

*  Methylprednisolone 4 mg tablets: Reliable and cheap online drugstore!

Methylprednisolone 4 mg tablets? Steroids and hormonal drugs! Genuine drugs online. ... Methylprednisolone 4 mg tablets: The best Canadian pills cheaply!. This just plain bad, viagra toronto I methylprednisolone 4 ... They methylprednisolone 4 mg tablets never seem to make my hair felt where can i buy lipitor in the uk soft and shiny. Very ... The methylprednisolone 4 mg tablets smell was horrible. If you want to know if I haven't found anything that has shown great ...

*  Methylprednisolone/neomycin topical Disease Interactions - Drugs.com

Comprehensive disease interaction information for methylprednisolone/neomycin topical. Includes Neomycin (Otic) - Perforated ... methylprednisolone / neomycin topical drug Interactions. There are 85 drug interactions with methylprednisolone / neomycin ... Neomycin (Otic) (Includes Methylprednisolone/neomycin topical) ↔ Perforated Tympanic Membrane. Severe Potential Hazard, High ... Topical Corticosteroids (Includes Methylprednisolone/neomycin topical) ↔ Diaper Rash. Moderate Potential Hazard, High ...

*  Methylprednisolone Equivalent Of Prednisone - Affordable Prices

Methylprednisolone Equivalent Of Prednisone. Discount Prescription Drugs From Our International Prescription Service. Best ... Methylprednisolone Equivalent Of Prednisone - Affordable Prices. Free pvi was achieved in b-icarbonate; of all differences with ... Sepkowitz ka, methylprednisolone equivalent of prednisone brown ae, armstrong d.. phenotypically, they are cheap mild in makes ... It is methylprednisolone equivalent of prednisone not upset headache to suppression breast much sweat assess study petitioner ...

*  Stem Cell Transplant for Inborn Errors of Metabolism - Full Text View - ClinicalTrials.gov

After hematopoietic cell transplant, subjects will then receive two drugs, cyclosporin and either methylprednisolone or ... Mycophenolate Mofetil (MMF). Cyclosporin and methylprednisolone or MMF are given to help prevent the complication of graft- ...

*  Prednisone Equivalent Methylprednisolone | Privacy & Confidentiality!

do back drive, methylprednisolone equivalent prednisone use cellulitis, or do any week that requires bicarbonate until you are ... otherwise, the methylprednisolone equivalent prednisone sample becomes inactive and india eq. your detail to donors can not ... If it is methylprednisolone equivalent prednisone only acetonide for your controlled prednisolone, take often that therapy. ... The prednisone equivalent methylprednisolone anti-inflammatory product produces three cell methods of pressive amounts which ...

*  Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer - Full Text View -...

Methylprednisolone Hemisuccinate. Prednisolone. Prednisolone acetate. Methylprednisolone acetate. Methylprednisolone. ... Arm I: Patients receive methylprednisolone IV weekly for 3 months. Arm II: Patients receive methylprednisolone IV and ... Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer. This study has been ... PURPOSE: Randomized phase III trial to compare the effectiveness of methylprednisolone with or without doxorubicin in treating ...

*  Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients - Full Text View -...

Methylprednisolone acetate. Methylprednisolone. Methylprednisolone Hemisuccinate. Prednisolone. Prednisolone hemisuccinate. ... Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients. This study has been ... Zufferey P, Bulliard C, Gremion G, Saugy M, So A. Systemic effects of epidural methylprednisolone injection on glucose ... at first comparing the glycaemic profile in diabetic patients after a unique injection of 80 mg of acetate methylprednisolone ...

*  Methylprednisolone Brands In India : Shipping And Delivery!

Methylprednisolone Brands In India. Save On Discount Prescription Drugs. Save 30% To 60% On Safe Prescription Drugs. Trusted ... Domains and methylprednisolone brands in india email of medical t-tests. Prednisolone may slow figure and doctor in experience ... Cats ih and methylprednisolone brands in india bs designed the much alcoholic tryptophan safety glucose and were involved in ... Further, methylprednisolone brands in india the contrast of this alcohol was not cortical and safely had a coronary treatment ...

*  Methylprednisolone DOSPAK For Electrical-Type Back Spasms?

... methylprednisolone - Answer: Yes, it can decrease the inflammation that is aggravating the nerves. I ... ... Home › Q & A › Questions › Methylprednisolone DOSPAK For.... Methylprednisolone DOSPAK For Electrical-Type Back Spasms?. Asked ... Methylprednisolone Information for Healthcare Professionals (includes dosage details). *Side Effects of Methylprednisolone ( ... shock, muscle spasm, methylprednisolone. Details:. My wife has been having severe back spasms & by back spasms, she says they ...

*  CiNii 論文 - Efficacy of Tonsillectomy Plus Methylprednisolone Pulse Therapy for a Child with...

Methylprednisolone pulse therapy in the treatment of severe forms of Schoenlein-Henoch purpura nephritis NIAUDET P. ... Efficacy of Tonsillectomy Plus Methylprednisolone Pulse Therapy for a Child with Henoch-Schoenlein Purpura Nephritis * * ... Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch- ...

*  METHYLPREDNISOLONE 1000 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/INFUSION | Drugs.com

Patient information for METHYLPREDNISOLONE 1000 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/INFUSION Including dosage ... 1. WHAT METHYLPREDNISOLONE IS AND. WHAT IT IS USED FOR. Methylprednisolone contains. methylprednisolone sodium succinate.. ... 1. What Methylprednisolone is and. what it is used for. 2. What you need to know before you. are given Methylprednisolone. 3. ... methylprednisolone and 3.2 mmol. (74.4mg) of sodium in each 1000mg. vial of methylprednisolone. If you are. on a controlled ...

*  Interactions between Methylprednisolone Sod Succ (PF) Injection and corticosteroids-hormonal-contraceptives-estrogens

WebMD provides information about interactions between Methylprednisolone Sod Succ (PF) Injection and corticosteroids-hormonal- ... Methylprednisolone Sod Suc(PF) Solution, Reconstituted (Recon Soln). Interactions. Corticosteroids/Hormonal Contraceptives; ... Treatment by Condition Related to Methylprednisolone Sod Succ (PF) Injection. *Prevention of Lung Transplant Rejection ...

*  Methylprednisolone - What happens if I don't take all the pills on the first day, my stomach was?

... methylprednisolone, doctor, stomach, pill - Additional details: ... hurting so I only took 3pills instead of six but my doctor ... Home › Q & A › Questions › Methylprednisolone - What.... Methylprednisolone - What happens if I don't take all the pills on the ... Methylprednisolone Information for Healthcare Professionals (includes dosage details). *Side Effects of Methylprednisolone ( ... methylprednisolone, doctor, stomach, pill. Details:. ... hurting so I only took 3pills instead of six but my doctor told me ...

*  Interactions between Methylprednisolone Acetate Injection and systemic-corticosteroids-live-vaccines

WebMD provides information about interactions between Methylprednisolone Acetate Injection and systemic-corticosteroids-live- ... Methylprednisolone Acetate Vial. Interactions. Systemic Corticosteroids/Live Vaccines. This information is generalized and not ... Treatment by Condition Related to Methylprednisolone Acetate Injection. *Eye Disorder Medications. *Liver Tissue Death ...

*  Methylprednisolone Hydrogen Succinate - Drugs.com

A list of US medications equivalent to Methylprednisolone Hydrogen Succinate is available on the Drugs.com website. ... Methylprednisolone Hydrogen Succinate is a medicine available in a number of countries worldwide. ... Ingredient matches for Methylprednisolone Hydrogen Succinate. Methylprednisolone. Methylprednisolone Hydrogen Succinate (BANM) ... Methylprednisolone Hydrogen Succinate. Methylprednisolone Hydrogen Succinate may be available in the countries listed below. ...

*  DailyMed - METHYLPREDNISOLONE- methylprednisolone tablet

METHYLPREDNISOLONE- methylprednisolone tablet To receive this label RSS feed. Copy the URL below and paste it into your RSS ... The initial dosage of Methylprednisolone Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the ... Methylprednisolone Tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, ... Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in ...

MethylprednisoloneBroad-Spectrum Chemokine Inhibitor: A Broad-Spectrum Chemokine Inhibitor or BSCI (also termed Chemotide or Somatotaxin ) is a type of experimental anti-inflammatory drug that inhibits the action of the pro-inflammatory proteins chemokines.Ameridose: Ameridose, LLC. is a large-scale compounding pharmacy based in Westborough, Massachusetts.PrednisoloneCombination therapy: Combination therapy or polytherapy is therapy that uses more than one medication or modality (versus monotherapy, which is any therapy taken alone). Typically, these terms refer to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression).Immunosuppressive drug: Immunosuppressive drugs or immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system. They are used in immunosuppressive therapy to:Adulterant: An adulterant is a substance found within other substances (e.g.AzathioprineMyelitisPlacebo-controlled study: Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham "placebo" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment.Cryosupernatant: The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted) refers to plasma from which the cryoprecipitate has been removed.Temporal analysis of products: Temporal Analysis of Products (TAP), (TAP-2), (TAP-3) is an experimental technique for studyingLennox–Gastaut syndrome

(1/1508) High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

We explored the combination of busulfan/cyclophosphamide/etoposide as conditioning regimen prior to bone marrow transplantation in 31 patients with acute myeloid leukemia (AML) in first complete remission. The preparative regimen consisted of 16 mg/kg busulfan, 30-60 mg/kg VP-16, and 120 mg/kg cyclophosphamide. With a median follow-up of 30.5 months (range, 5-60 months), 25 patients are alive in continuous complete remission. Estimated disease-free survival at 5 years is 80.5%. Death was due to transplant-related toxicity (graft-versus-host disease and cytomegalovirus infection, graft-versus-host disease and pneumonia, sepsis and mucositis, respectively). None of the patients have relapsed. As demonstrated by the results of this analysis, the conditioning regimen busulfan/cyclophosphamide/etoposide is effective and well tolerated in patients with AML in first complete remission. Main nonhematological toxicities were mucositis and hepatotoxicity. The low mortality and relapse rate appears to justify allogeneic bone marrow transplantation for patients with AML in first complete remission who have an HLA-identical donor. Whether this regimen offers a substantial improvement in disease-free and overall survival over presently used regimens warrants further investigation.  (+info)

(2/1508) Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment.

OBJECTIVES: A generalised transient improvement may follow intra-articular administration of glucocorticoids to patients with inflammatory arthropathy. This may represent a systemic anti-inflammatory effect of glucocorticoid released from the joint, mediated through processes such as altered leucocyte trafficking or suppressed release of pro-inflammatory cytokines. Patients, who had received intra-articular injections of glucocorticoids were therefore studied for evidence of these two systemic effects. METHODS: Patients with rheumatoid arthritis were studied. Peripheral blood leucocyte counts, tumour necrosis factor alpha (TNF alpha) release by peripheral blood monocytes, blood cortisol concentrations, and blood methylprednisolone concentration were measured for 96 hours after intra-articular injection of methylprednisolone acetate. RESULTS: Measurable concentrations of methylprednisolone were present in blood for up to 96 hours after injection. Significant suppression of the hypothalamic-pituitary-adrenal axis persisted throughout this time. Altered monocyte and lymphocyte trafficking, as evidenced by peripheral blood monocytopenia and lymphopenia, was apparent by four hours after injection and resolved in concordance with the elimination of methylprednisolone. Granulocytosis was observed at 24 and 48 hours. Release of TNF alpha by endotoxin stimulated peripheral blood monocytes was suppressed at four hours and thereafter. Suppression was maximal at eight hours and was largely reversed by the glucocorticoid antagonist, mifepristone. CONCLUSIONS: After intra-articular injection of methylprednisolone, blood concentrations of glucocorticoid are sufficient to suppress monocyte TNF alpha release for at least four days and to transiently alter leucocyte trafficking. These effects help to explain the transient systemic response to intra-articular glucocorticoids. Suppression of TNF alpha is principally a direct glucocorticoid effect, rather than a consequence of other methylprednisolone induced changes to blood composition.  (+info)

(3/1508) ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.

BACKGROUND: The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin, has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We were interested in determining whether this regimen would be effective and tolerable for Chinese patients. METHODS: Thirty-two patients with refractory/relapsed non-Hodgkins lymphoma (23 intermediate-grade and nine high-grade) were enrolled in this study. Etoposide was administered at a dose of 40 mg/m2/day as a 1 h intravenous infusion from day 1 to day 4, solumedrol 500 mg/day was given as a 15 min intravenous infusion from day 1 to day 5, ara-C 2 g/m2 was given as a 2 h intravenous infusion on day 5 and cisplatin was given at a dose of 25 mg/m2/day as a continuous infusion from day 1 to day 4. Clinical efficacy and toxicity were assessed on the basis of the WHO criteria. RESULTS: Ten patients (31.3%, 95% Cl 15.2-47.4%) attained complete remission (CR) and seven had partial remission (PR). The overall response rate was 53.1% (95% Cl 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC < 1000/microliter) lasted for an average of 12 days and thrombocytopenia (< 25,000/microliter) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2, 22% grade 3), stomatitis in 72% (25% grade 2, 28% grade 3, 13% grade 4), hepatotoxicity in 9% (3% grade 2), renal toxicity in 13% (6% grade 2, 3% grade 3) and infection in 56% (18% grade 2, 25% grade 3, 13% grade 4). The majority of the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months. CONCLUSIONS: ESHAP is an active and tolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival.  (+info)

(4/1508) Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.

In order to determine whether doses of cyclosporine and methylprednisolone used for prophylaxis and therapy of acute graft-versus-host disease (GVHD) have any influence on relapse and survival following allogeneic bone marrow transplantation (BMT), we studied 176 adult patients with hematologic malignancies, who underwent a first allogeneic transplant from an HLA-identical sibling donor. Two methods of management of acute GVHD used in two different centers were compared: group I included 62 patients who had 'standard' management of GVHD including prophylaxis with 1-3 mg/kg/day of cyclosporine and treatment with 2 mg/kg/day of methylprednisolone when acute GVHD developed; group II included 114 patients who received 'intensive' management of GVHD including prophylaxis with 5 mg/kg/day of cyclosporine and treatment with high-dose methylprednisolone (8-20 mg/kg/day for 3 days) at the onset of GVHD. The overall incidence of GVHD was the same in both groups. However, acute GVHD was more severe in group I than in group II (P < 0.0001), with consequently less resolution of GVHD after treatment in group I (61%) than in group II (80%) (P = 0.06). Overall survival and disease-free survival (DFS) did not differ between the two groups. However, actuarial risk of disease relapse was significantly higher in group II than in group I (36% vs 17%, P = 0.02). In a multivariate analysis taking into account known factors influencing GVHD and relapse, only type of GVHD management and age were significantly predictive for the occurrence of GVHD, while only type of GVHD management and pathology other than chronic myeloid leukemia (CML) were predictive for relapse. This study demonstrates that intensity of GVHD prophylaxis and therapy can influence the graft-versus-leukemia effect by decreasing severity of GVHD but at the price of increasing relapse rate post transplant.  (+info)

(5/1508) Latent Pneumocystis carinii infection in commercial rat colonies: comparison of inductive immunosuppressants plus histopathology, PCR, and serology as detection methods.

Histopathologic evaluation combined with a period of immunosuppression has been the standard procedure for detection of Pneumocystis carinii in commercial rat colonies. Variation in induction regimens and in the sensitivity of detection methods may result in underreporting of the presence of P. carinii in breeding colonies or delay its detection. In the present study, methylprednisolone and cyclophosphamide were evaluated for the ability to induce P. carinii infection in rats from an enzootically infected commercial barrier colony. The presence of P. carinii was detected by histopathologic methods and by amplification of a targeted region of the P. carinii thymidylate synthase gene by PCR over the 8-week study period. Sera taken from rats prior to either induction regimen were evaluated for the presence of P. carinii-specific antibodies by the immunoblotting technique. Few significant differences in ability to induce organism burden or in histopathology were observed between the two immunosuppressive regimens. However, a dramatic loss of weight over the study period was observed in rats treated with methylprednisolone but not in rats treated with cyclophosphamide. Although histopathologic changes attributable to P. carinii did not appear before 2 weeks with either immunosuppressant, the presence of the organism in these animals was detected by immunoblotting and PCR. Cyst scores and the intensities of the histopathologic lesions increased during the study period, but the number of rats exhibiting evidence of P. carinii infection did not change after week 3. These results suggest that use of the PCR method on postmortem lung tissue of rats without prior induction regimens or identification of anti-P. carinii antibodies in antemortem serum samples is a sufficiently sensitive method for detection of the presence of a P. carinii carrier state in rodent breeding colonies.  (+info)

(6/1508) Western immunoblot analysis of the antigens of Haemobartonella felis with sera from experimentally infected cats.

Cats were experimentally infected with a Florida isolate of Haemobartonella felis in order to collect organisms and evaluate the immune response to H. felis. Cryopreserved organisms were thawed and injected intravenously into nonsplenectomized and splenectomized cats. Splenectomized animals were given 10 mg of methylprednisolone per ml at the time of inoculation. Blood films were evaluated daily for 1 week prior to infection and for up to 60 days postinfection (p. i.). Blood for H. felis purification was repeatedly collected from splenectomized animals at periods of peak parasitemias. Organisms were purified from infected blood by differential centrifugation, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes for immunoblot analysis. Serum was collected from nonsplenectomized animals prior to and for up to 60 days p.i. and was used on immunoblots to identify antigens. The combination of splenectomy and corticosteroid treatment resulted in marked, cyclic parasitemias without concurrent severe anemia, providing an opportunity to harvest organisms in a manner that was not lethal to the animals. Several antigens (150, 52, 47, 45, and 14 kDa) were identified. An antigen with a molecular mass of approximately 14 kDa appeared to be one of the most immunodominant and was consistently recognized by immune sera collected at various times during the course of infection. These data suggest that one or more of these antigens might be useful for the serologic diagnosis of H. felis infections in cats.  (+info)

(7/1508) Dermatomyositis associated with invasive thymoma.

We report a case of dermatomyositis (DM) associated with invasive thymoma in a 22-year-old woman who was admitted to our hospital complaining of dyspnea which required ventilation support. The reddened elevated scaly eruptions were prominent over the extensor surfaces. Chest X-ray and computed tomography showed mediastinal masses, which were diagnosed as mixed type thymoma. Muscle and skin biopsy specimens were compatible with DM. She was treated with methylprednisolone pulse therapy followed by extended removal of the anterior mediastinal tumor and subsequent radiotherapy. She has had a good clinical course without recurrence of thymoma or DM for more than 3 years. The role of thymoma in the development of DM is discussed.  (+info)

(8/1508) Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin.

Previously we reported that 8-week treatment with methylprednisolone acetate (MPA: 0.1 mg/kg, s.c., 3 days a week) of male rats caused a novel type of osteopenia whose development was prevented by salmon calcitonin (SCT) in a dose-dependent manner. In this study, to compare the MPA-inducible osteopenia with the ovariectomy (OVX)-inducible one, female rats were used instead of male rats and a time-course study of development was made. MPA treatments for 1, 2, 4 and 8 weeks histologically induced characteristic osteopenic changes in a time-dependent manner that were histomorphometrically detectable in tibiae within 4 weeks as reduced bone mass, accelerated bone resorption, and suppressed bone formation and mineralization. Node-strut analysis revealed that the connectivity of the trabecular structure remained unaffected. Such MPA-induced changes in the trabecular structure, to be defined as thinned-but-uncut, is in a good contrast with OVX-induced unthinned-but-cut structure, although the latter osteopenic changes became detectable 2 weeks earlier. Another previous finding confirmed herein was that MPA-induced osteopenia in female rats was also completely masked by SCT (10 U/kg, s.c., 5 days a week). The results indicate that the MPA-inducible secondary osteopenic model in either sex of rats would be usable for testing anti-osteopenic drugs.  (+info)



acetate

  • CDC urges clinicians to contact patients who have received medicines associated with 3 lots of preservative-free methylprednisolone acetate from the New England Compounding Center that were recalled on September 26. (apta.org)
  • These compounded steroid injections (methylprednisolone acetate) being investigated as part of the outbreak were NOT approved by the agency," wrote Erica V. Jefferson, FDA spokeswoman, in an email to USA Today . (redorbit.com)
  • In response to the outbreak, state and federal regulators are looking into the shipments of NECC to understand why the company shipped methylprednisolone acetate steroid that was free of preservatives. (redorbit.com)